Natasha Leighl
Natasha Leighl
Medical Oncology, Princess Margaret
Verified email at
Cited by
Cited by
Pembrolizumab for the treatment of non–small-cell lung cancer
EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ...
New England Journal of Medicine 372 (21), 2018-2028, 2015
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer: AVAiL
M Reck, J von Pawel, P Zatloukal, R Ramlau, V Gorbounova, V Hirsh, ...
Journal of Clinical Oncology 27 (8), 1227-1234, 2009
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline
JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ...
Journal of clinical oncology: official journal of the American Society of …, 2018
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
C Zimmermann, N Swami, M Krzyzanowska, B Hannon, N Leighl, A Oza, ...
The Lancet 383 (9930), 1721-1730, 2014
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III …
M Reck, J Von Pawel, P Zatloukal, R Ramlau, V Gorbounova, V Hirsh, ...
Annals of oncology 21 (9), 1804-1809, 2010
Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis
RG Hagerty, PN Butow, PM Ellis, EA Lobb, SC Pendlebury, N Leighl, ...
Journal of clinical oncology 23 (6), 1278-1288, 2005
Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update
TJ Smith, K Bohlke, GH Lyman, KR Carson, J Crawford, SJ Cross, ...
Journal of Clinical Oncology 33 (28), 3199-3212, 2015
Cancer patient preferences for communication of prognosis in the metastatic setting
R Hagerty, P Butow, P Ellis, E Lobb, S Pendlebury, N Leighl, D Goldstein, ...
Journal of clinical oncology 22 (9), 1721-1730, 2004
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature
G D'Addario, M Pintilie, NB Leighl, R Feld, T Cerny, FA Shepherd
Journal of clinical oncology 23 (13), 2926-2936, 2005
Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial
DW Kim, M Tiseo, MJ Ahn, KL Reckamp, KH Hansen, SW Kim, RM Huber, ...
Journal of Clinical Oncology 35 (22), 2490-2498, 2017
Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
N Hanna, D Johnson, S Temin, S Baker Jr, J Brahmer, PM Ellis, ...
Journal of Clinical Oncology, 2017
Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials
TR Asmis, K Ding, L Seymour, FA Shepherd, NB Leighl, TL Winton, ...
Journal of Clinical Oncology 26 (1), 54-59, 2008
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of …
NB Leighl, N Rekhtman, WA Biermann, J Huang, M Mino-Kenudson, ...
Journal of clinical oncology 32 (32), 3673, 2014
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials
M Di Maio, C Gallo, NB Leighl, MC Piccirillo, G Daniele, F Nuzzo, ...
Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non …
C Manegold, J Von Pawel, P Zatloukal, R Ramlau, V Gorbounova, ...
Journal of Clinical Oncology 25 (18_suppl), LBA7514-LBA7514, 2007
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma
M de Perrot, R Feld, BCJ Cho, A Bezjak, M Anraku, R Burkes, H Roberts, ...
Journal of Clinical Oncology 27 (9), 1413-1418, 2009
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial
C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts, V Gebbia, P Maione, ...
J Clin Oncol 30 (24), 3002-3011, 2012
Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study
EB Garon, MD Hellmann, NA Rizvi, E Carcereny, NB Leighl, MJ Ahn, ...
Journal of Clinical Oncology 37 (28), 2518, 2019
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 …
GD Goss, A Arnold, FA Shepherd, M Dediu, TE Ciuleanu, D Fenton, ...
J Clin Oncol 28 (1), 49-55, 2010
The system can't perform the operation now. Try again later.
Articles 1–20